Full-Time

Robotic Sales Associate

Westchester

Posted on 4/8/2025

PROCEPT BioRobotics

PROCEPT BioRobotics

501-1,000 employees

Robotic system enabling Aquablation BPH treatment

Compensation Overview

$90k/yr

+ Bonus + Equity

Westchester County, NY, USA

Remote

Category
Sales & Account Management (1)
Required Skills
Customer Service
Requirements
  • Bachelor’s degree from accredited reputable institution
  • A minimum of two years of experience in medical and capital sales within the Operating Room
  • Start-up company experience selling disruptive surgical technology
  • Strong local relationships within the healthcare community in specified geographic area
  • Ability to travel upwards to 75%
Responsibilities
  • Meet or exceed quarterly sales quota for the defined area
  • Work with the sales manager to develop a plan that outlines sales objectives tailored to the local market
  • Manage the complex sales process of the Hydros Robotic System into new and existing hospitals
  • Build clinical and administrative support through technical presentations, executive meetings, and marketing events
  • Build support from surgeons and administration for Aquablation therapy
  • Identify key institutions, generate market awareness, and drive sales of the Hydros System within an assigned sales territory
  • Effectively manage transition of initial sale and installation to the Aquablation sales team to drive procedural volume and growth
  • Develop initial contact with CEO and senior hospital administrators
  • Provide monthly forecasts for defined area
  • Effectively communicate Hydros’s value proposition to customers
  • Build and maintain relationships with key customers and KOLs within region
  • Partner closely with Sales Management and the Marketing team to identify and prioritize customers for higher-level corporate relationships
  • Partner with the Customer Service team to meet and exceed customer expectations
  • Ensure all required sales reporting forms are completed and submitted on time
  • Maintain records in the PROCEPT CRM system on contacts and facilities
  • Provide support in the resolution of product complaints and/or safety issues
  • Proactively support organizational goals and objectives, policies and procedures, and FDA regulations including strict compliance with PROCEPT’s Customer Relationship and the Sunshine Act policies
  • Maintain a professional and credible image with customers and teammates
  • Establish and maintain credentials to enter and work in hospitals and other medical facilities as required by facility requirements
  • Manage travel and expenses per approved budget
  • Maintain trained status for, and comply with, all relevant aspects of the PROCEPT BioRobotics Quality Management System to ensure product and support regulatory compliance
  • Understand and adhere to the PROCEPT BioRobotics Quality and EHS policies
Desired Qualifications
  • Leadership skills as demonstrated through past professional performance, involvement in sports, professional clubs, or associations
  • robotics experience

PROCEPT BioRobotics develops robotic medical devices for treating enlarged prostate (BPH). Its flagship AquaBeam Robotic System enables Aquablation therapy, a minimally invasive procedure that removes prostate tissue using a waterjet guided by real-time imaging and robotics to achieve precise, reproducible tissue removal. The system is designed for use by urologists in hospitals and clinics, and the company monetizes through the sale of the AquaBeam system, ongoing revenue from disposable procedure components, and training and support services for providers. Compared with competitors, PROCEPT focuses on a controlled, image-guided robotic approach that aims for predictable outcomes and fewer complications, and its technology has gained recognition in clinical practice guidelines. The company’s goal is to improve patient quality of life by delivering accurate, efficient, and minimally invasive BPH treatment that reduces urinary symptoms using a repeatable surgical workflow.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 system ASP reached record $485K, up 14% QoQ, exceeding guidance.
  • International HYDROS launch in UK March 2026 expands addressable market beyond US.
  • 250 peer-reviewed publications and NICE approval strengthen clinical evidence and adoption barriers.

What critics are saying

  • Missed 2025 EBITDA guidance by $15.2M; shareholder litigation erodes investor confidence.
  • Unprofitable with $95.57M trailing net loss; requires profitability by 2027 or dilutive financing.
  • Competitors Boston Scientific and Intuitive Surgical entering BPH robotics threaten market share.

What makes PROCEPT BioRobotics unique

  • Only AI-powered, ultrasound-guided, heat-free robotic waterjet for BPH treatment.
  • EAU strong recommendation March 2026 validates Aquablation over TURP and laser alternatives.
  • Larry Wood from Edwards Lifesciences TAVR leadership brings 18-year medtech scaling expertise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Parental Leave

Paid Holidays

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Mar 26th, 2026
PROCEPT BioRobotics launches AI-enabled HYDROS system in UK, hits 900 global installations

PROCEPT BioRobotics has launched its HYDROS robotic system internationally, with the UK as the first market outside the US. The AI-enabled platform uses real-time ultrasound imaging and robotic precision for treating benign prostatic hyperplasia. The company reported fourth-quarter revenue of $76.4 million and full-year revenue of $308.1 million, representing 37% growth. PROCEPT ended 2025 with 718 systems installed in the US and over 900 globally. For fiscal year 2026, management expects revenue to grow 27% to 33%, reaching $390 million to $410 million. The HYDROS launch expands the company's international presence whilst strengthening its position in minimally invasive urologic procedures.

PT Riau One Media Group
Mar 23rd, 2026
EAU Guidelines upgrade Aquablation therapy to strong surgical recommendation for BPH.

EAU Guidelines upgrade Aquablation therapy to strong surgical recommendation for BPH. Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia SAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) - PROCEPT BioRobotics (Nasdaq: PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for men with benign prostatic hyperplasia (BPH). The EAU guidelines are widely regarded as one of the most rigorous and influential clinical guideline frameworks in urology globally. The updated guidelines now strongly recommend offering Aquablation therapy as an alternative to transurethral resection of the prostate (TURP) for men with moderate-to-severe urinary symptoms due to BPH, particularly for patients interested in preserving ejaculatory function. This upgrade indicates strong evidence quality and a favorable balance between benefit, harm, and patient preference. Discover more Prostate Surgery Alternatives TURP Alternative Information Health Conditions Guidelines are supported by outcomes from multiple clinical trials on Aquablation therapy, including WATER, a randomized trial against TURP, and WATER II trials demonstrating durable improvements in urinary symptoms and preservation of sexual and urinary function. The guidelines also now recognize evidence supporting Aquablation therapy across a broad range of prostate anatomies, including larger prostate glands, with additional evidence continuing to emerge from recently published studies such as WATER III, a randomized trial against laser enucleation in large glands. "The strength of the clinical evidence supporting Aquablation therapy continues to grow, and this guideline upgrade from the European Association of Urology represents an important milestone for Aquablation therapy," said Larry Wood, President and Chief Executive Officer of PROCEPT BioRobotics. "A strong recommendation from one of the most respected global guideline bodies reflects the strength of the clinical evidence supporting Aquablation therapy and reinforces its role as a modern surgical option for physicians seeking to deliver durable symptom relief while preserving quality-of-life outcomes that matter most to patients," said Evangelos Liatsikos, MD, PhD, Professor of Urology and Chairman of the Department of Urology at the University of Patras, Greece, and Chairman of the European School of Urology (ESU). Recognition from the EAU adds to growing international clinical validation for Aquablation therapy, including support from health technology assessment bodies such as the National Institute for Health and Care Excellence (NICE) in the United Kingdom supporting the routine use of Aquablation therapy within the NHS. About PROCEPT BioRobotics Corporation PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Forward-Looking Statements This press release may contain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in such statements. PROCEPT BioRobotics undertakes no obligation to publicly update or revise any forward-looking statements. Important Safety Information All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/ Media Contact: Discover more Urology surgical instruments Minimally Invasive Surgery BPH diagnostic kits Matt Bacso Vice President, Investor Relations and Business Operations PROCEPT BioRobotics [email protected]

Yahoo Finance
Mar 12th, 2026
PROCEPT BioRobotics launches AI-enabled HYDROS Robotic System in UK for BPH treatment

PROCEPT BioRobotics has launched its HYDROS Robotic System internationally, beginning in the UK, with further expansion planned for 2026. The AI-enabled platform delivers Aquablation therapy for treating benign prostatic hyperplasia. HYDROS uses AI-interpreted real-time ultrasound imaging and advanced treatment planning to enable surgeons to deliver personalised therapy with robotic precision. Clinical evidence shows Aquablation provides durable symptom relief whilst preserving sexual and urinary function. The system combines surgeon judgement with robotic execution, allowing physicians to specify which prostate areas to remove whilst preserving anatomy controlling erectile function, ejaculatory function and continence. The platform is designed to support scalable adoption across healthcare settings whilst maintaining consistent procedural outcomes. Aquablation therapy is ultrasound-guided, robotic-assisted and heat-free.

GlobeNewswire
Mar 12th, 2026
PROCEPT BioRobotics(R) Announces International Launch of the HYDROS(R) Robotic System, Expanding Global Access to AI-Enabled Aquablation(R) Therapy

PROCEPT BioRobotics(R) announces international launch of the HYDROS(R) Robotic System, expanding global access to ai-enabled aquablation(r) therapy. UK marks first international launch of the HYDROS Robotic System, with additional international expansion planned in 2026. SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) - PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care settings while maintaining consistent procedural execution. Aquablation therapy offers a complete solution for men living with BPH. A robust body of clinical evidence continues to demonstrate Aquablation delivers durable symptom relief while preserving sexual and urinary function, outcomes that are critically important to patients. "Many men living with BPH remain on long-term medication or delay surgery because they are concerned about potential trade-offs between symptom relief and side effects," said Larry Wood, President & CEO, PROCEPT BioRobotics. "The HYDROS Robotic System expands international access to a clinically validated, next-generation AI-enabled robotic solution that delivers durable symptom relief while preserving quality of life. We are proud to bring this innovation to physicians and patients across the UK and to continue expanding our international footprint." "The HYDROS Robotic System brings AI-enabled, real-time ultrasound-guidance and robotic assisted treatment planning to NICE-recommended Aquablation therapy in the UK, supporting precise, anatomy-specific treatment," said Mr. Neil Barber, Consultant Urological Surgeon. "By combining surgeon judgement with robotic precision, Aquablation with HYDROS enables durable symptom relief and preservation of quality-of-life outcomes, including sexual and urinary function and meaningfully expands surgical choice for men living with BPH." About Aquablation Therapy Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system's real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient's unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion. About PROCEPT BioRobotics(R) Corporation PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM(R) and HYDROS Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Forward-Looking Statements This press release may contain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in such statements. PROCEPT BioRobotics undertakes no obligation to publicly update or revise any forward-looking statements. Important Safety Information All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/ Media Contact: Matt Basco Vice President, Investor Relations and Business Operations PROCEPT BioRobotics [email protected]

PR Newswire
Mar 4th, 2026
Procept BioRobotics posts $50.2M EBITDA loss vs. $35M projected as shares drop 15%

Procept BioRobotics faces investor investigation after reporting a full-year 2025 adjusted EBITDA loss of $50.2 million, significantly worse than the $35 million projected by CFO Kevin Waters during the Q3 earnings call. The $15.2 million gap represents a 43% deviation from guidance. The company also missed revenue targets, reporting $308.1 million against guidance of $325.5 million. Fourth-quarter EPS came in at -$0.53 versus analyst consensus of -$0.32, a 66% miss. Shares fell more than 15% following the disclosure. Law firm Levi & Korsinsky is investigating potential securities claims on behalf of shareholders who suffered losses, citing discrepancies between management's projections and actual financial results.

INACTIVE